Given the changing reimbursement mechanisms and treatment guidelines for direct acting antivirals (DAAs) for the treatment of hepatitis C, this study aimed to understand the characteristics of individuals prescribed DAAs and the specialty of prescribing physicians between 2012 and 2018 in Ontario.
To help characterize the impact of COVID-19 on drug prescribing, this newly released tool provides public access to data on drug utilization in Ontario during the COVID-19 pandemic
This study examines the association between initial opioid prescription characteristics and the risk of overdose and long-term opioid use among new prescription opioid recipients.
This study examines whether changes implemented to the Ontario Naloxone Program for Pharmacies in March 2018 impacted the distribution of naloxone through the program in Ontario.
This report describes the preliminary patterns in circumstances surrounding opioid-related deaths in Ontario during COVID-19. An understanding of these circumstances is urgently needed to inform interventions and policies to prevent further opioid-related mortality in the midst of this pandemic.